Cargando…

CA-125–indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery

BACKGROUND: There is no consensus regarding the management of ovarian cancer patients, who have shown complete clinical response (CCR) to primary therapy and have rising cancer antigen CA-125 levels but have no symptoms of recurrent disease. The present study aims to determine whether follow-up CA-1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Fang, Ye, Yanfen, Xu, Xia, Zhou, Xuehui, Wang, Jinhua, Chen, Xiaoxiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576242/ https://www.ncbi.nlm.nih.gov/pubmed/23402322 http://dx.doi.org/10.1186/1757-2215-6-14

Ejemplares similares

The role of CA-125, GLS and FASN in predicting cytoreduction for epithelial ovarian cancers
por: Winarno, G. N. A., et al.
Publicado: (2020)

Morbidity and mortality in women with advanced ovarian cancer who underwent primary cytoreductive surgery compared to cytoreductive surgery for recurrent disease: a meta-analysis
por: Bartels, Helena C., et al.
Publicado: (2019)

Predicting value of HE4 and CA125 markers for optimal cytoreductive surgery in ovarian cancer patients
por: Saffarieh, Elham, et al.
Publicado: (2022)

Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer
por: Xu, Xia, et al.
Publicado: (2013)

Efficacy of dexmedetomidine as an adjunct to ropivacaine in bilateral dual-transversus abdominis plane blocks in patients with ovarian cancer who underwent cytoreductive surgery
por: Zhang, Jian-ping, et al.
Publicado: (2022)

Preoperative Serum CA-125 Level As a Predictor for The Extent of Cytoreduction in Patients with Advanced Stage Epithelial Ovarian Cancer
por: Merlo, Sebastjan, et al.
Publicado: (2021)

Retraction Note: Efficacy of dexmedetomidine as an adjunct to ropivacaine in bilateral dual-transversus abdominis plane blocks in patients with ovarian cancer who underwent cytoreductive surgery
por: Zhang, Jian-ping, et al.
Publicado: (2022)

Survival in Advanced-Stage Epithelial Ovarian Cancer Patients with Cardiophrenic Lymphadenopathy Who Underwent Cytoreductive Surgery: A Systematic Review and Meta-Analysis
por: Kengsakul, Malika, et al.
Publicado: (2021)

Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study
por: Feng, Li-yuan, et al.
Publicado: (2020)

Clinical Significance of Mesenchymal Circulating Tumor Cells in Patients With Oligometastatic Hormone-Sensitive Prostate Cancer Who Underwent Cytoreductive Radical Prostatectomy
por: Yang, Guanjie, et al.
Publicado: (2022)

Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer
por: Xu, Xia, et al.
Publicado: (2013)

Which patients benefit from secondary cytoreductive surgery in recurrent ovarian cancer?
por: Zang, Rongyu, et al.
Publicado: (2019)

CA125 in ovarian tumour tissue at second laparotomy.
por: Maughan, T. S., et al.
Publicado: (1989)

HE4, CA-125, and cystic ovarian mass
por: Wiwanitkit, Viroj
Publicado: (2012)

CA125 and Ovarian Cancer: A Comprehensive Review
por: Charkhchi, Parsa, et al.
Publicado: (2020)

Cytoreductive surgery in ovarian cancer
por: Pomel, Christophe, et al.
Publicado: (2007)

Deciphering the Molecular Nature of Ovarian Cancer Biomarker CA125
por: Weiland, Florian, et al.
Publicado: (2012)

The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study
por: Bai, Huimin, et al.
Publicado: (2016)

The effect of prophylactic bilateral salpingectomy on ovarian reserve in patients who underwent laparoscopic hysterectomy
por: Wang, Shizhuo, et al.
Publicado: (2021)

CA19-9 as a marker for ovarian cancer: alone and in comparison with CA125.
por: Canney, P. A., et al.
Publicado: (1985)

The Value of CA 125 and CA72-4 in Management of Patients with Epithelial Ovarian Cancer
por: Fayed, Salah T., et al.
Publicado: (1998)

The outcomes of isolated ureteral resection and reconstruction in non-urologic cancer patients who underwent cytoreductive surgery (CRC) and hyperthermic intraperitoneal chemotherapy (HIPEC)
por: Morkavuk, Şevket Barış, et al.
Publicado: (2019)

Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.
por: Mogensen, O., et al.
Publicado: (1990)

Preoperative Cancer Antigen 125 Level as Predictor for Complete Cytoreduction in Ovarian Cancer: A Prospective Cohort Study and Systematic Review
por: Brons, Puck E., et al.
Publicado: (2022)

CA125-Tn ELISA assay improves specificity of pre-operative diagnosis of ovarian cancer among patients with elevated serum CA125 levels
por: Wang, Yi-Sheng, et al.
Publicado: (2021)

The effect of CA125 on metastasis of ovarian cancer: old marker new function
por: Yuan, Qin, et al.
Publicado: (2017)

Reduction of CA125 Levels During Neoadjuvant Chemotherapy Can Predict Cytoreduction to No Visible Residual Disease in Patients with Advanced Epithelial Ovarian Cancer, Primary Carcinoma of Fallopian tube and Peritoneal Carcinoma
por: Zeng, Jing, et al.
Publicado: (2016)

Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer.
por: Rustin, G. J., et al.
Publicado: (1996)

Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer
por: Tcherkassova, Janneta, et al.
Publicado: (2011)

TB Peritonitis Mistaken for Ovarian Carcinomatosis Based on an Elevated CA-125
por: Boss, Joseph D., et al.
Publicado: (2012)

Is CA125 useful in monitoring patients with platinum-resistant ovarian cancer?
por: Rustin, G. J. S., et al.
Publicado: (2016)

Exosomal CA125 as A Promising Biomarker for Ovarian Cancer Diagnosis
por: Chen, Zhixiang, et al.
Publicado: (2020)

Combined Preoperative LMR and CA125 for Prognostic Assessment of Ovarian Cancer
por: Tang, Ying, et al.
Publicado: (2020)

VCAM-1 complements CA-125 in detecting recurrent ovarian cancer
por: Song, Jin, et al.
Publicado: (2023)

Ligand-based adoptive T cell targeting CA125 in ovarian cancer
por: Zhao, Haihong, et al.
Publicado: (2023)

Serum CA19‐9, CA‐125 and CEA as tumor markers for mucinous ovarian tumors
por: Lertkhachonsuk, Arb‐aroon, et al.
Publicado: (2020)

Relationship of tumor marker CA125 and ovarian tumor stem cells: preliminary identification
por: Zhang, Hui, et al.
Publicado: (2015)

The added value of CA125, HE4, and CA72-4 as markers for ovarian endometriosis diagnosis
por: Micu, Romeo, et al.
Publicado: (2023)

Quality of Life of Patients With Nasal Obstruction Who Underwent Septoplasty: Assessed With the Glasgow Benefit Inventory
por: Alkholaiwi, Feras
Publicado: (2023)

Laparoscopic Cytoreduction for Primary Advanced Ovarian Cancer
por: Fanning, James, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_irf29kmad3cd8820rlamegv36o